IL296823A - Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity - Google Patents
Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activityInfo
- Publication number
- IL296823A IL296823A IL296823A IL29682322A IL296823A IL 296823 A IL296823 A IL 296823A IL 296823 A IL296823 A IL 296823A IL 29682322 A IL29682322 A IL 29682322A IL 296823 A IL296823 A IL 296823A
- Authority
- IL
- Israel
- Prior art keywords
- dynamicpdf
- pmol
- mixture
- unlicensed
- evaluating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063001640P | 2020-03-30 | 2020-03-30 | |
| PCT/EP2021/058099 WO2021198149A1 (en) | 2020-03-30 | 2021-03-29 | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL296823A true IL296823A (en) | 2022-11-01 |
Family
ID=75362607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL296823A IL296823A (en) | 2020-03-30 | 2021-03-29 | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11780827B2 (https=) |
| EP (1) | EP4126850B1 (https=) |
| JP (1) | JP7617134B2 (https=) |
| KR (1) | KR20220161454A (https=) |
| CN (1) | CN115697997B (https=) |
| AR (1) | AR121675A1 (https=) |
| AU (1) | AU2021250303A1 (https=) |
| BR (1) | BR112022018996A2 (https=) |
| CA (1) | CA3176265A1 (https=) |
| CO (1) | CO2022014886A2 (https=) |
| CR (1) | CR20220554A (https=) |
| DO (1) | DOP2022000203A (https=) |
| EC (1) | ECSP22080683A (https=) |
| IL (1) | IL296823A (https=) |
| JO (1) | JOP20220235A1 (https=) |
| MX (1) | MX2022012067A (https=) |
| PE (1) | PE20221918A1 (https=) |
| PH (1) | PH12022552553A1 (https=) |
| TW (1) | TW202204343A (https=) |
| WO (1) | WO2021198149A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202206413A (zh) | 2020-04-22 | 2022-02-16 | 美商紐羅克里生物科學有限公司 | Gpr52調節劑及其使用方法 |
| US12115157B2 (en) | 2021-09-14 | 2024-10-15 | Boehringer Ingelheim International Gmbh | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament |
| CN119143731B (zh) * | 2024-09-13 | 2025-08-26 | 中国海洋大学 | 一种吡嗪酰胺类化合物及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2055500A (en) * | 1998-12-23 | 2000-07-31 | Eli Lilly And Company | Aromatic amides |
| WO2009107391A1 (ja) | 2008-02-27 | 2009-09-03 | 武田薬品工業株式会社 | ６員芳香環含有化合物 |
| GB0808668D0 (en) * | 2008-05-13 | 2008-06-18 | Univ Aberdeen | Materials and methods relating to a G-protein coupled receptor |
| JPWO2009157196A1 (ja) | 2008-06-25 | 2011-12-08 | 武田薬品工業株式会社 | アミド化合物 |
| WO2011078360A1 (ja) * | 2009-12-24 | 2011-06-30 | 武田薬品工業株式会社 | アミド化合物 |
| EP2530078A1 (en) * | 2010-01-27 | 2012-12-05 | Takeda Pharmaceutical Company Limited | Thiazole derivative |
| WO2011145735A1 (ja) * | 2010-05-21 | 2011-11-24 | 武田薬品工業株式会社 | チアゾール誘導体 |
| WO2012020738A1 (ja) * | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
| WO2012076063A1 (en) * | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| KR20180004193A (ko) * | 2015-04-29 | 2018-01-10 | 아레나 파마슈티칼스, 인크. | Gpr52와 관련된 장애의 치료 또는 예방을 위한 gpr52 조절제로서 1-헤테로아릴-인돌린-4-카르복스아미드 |
| AU2016324317A1 (en) * | 2015-09-17 | 2018-03-08 | Coda Biotherapeutics, Inc. | Compositions and methods for treating neurological disorders |
-
2021
- 2021-03-29 BR BR112022018996A patent/BR112022018996A2/pt not_active Application Discontinuation
- 2021-03-29 AR ARP210100766A patent/AR121675A1/es not_active Application Discontinuation
- 2021-03-29 KR KR1020227038002A patent/KR20220161454A/ko not_active Withdrawn
- 2021-03-29 CR CR20220554A patent/CR20220554A/es unknown
- 2021-03-29 AU AU2021250303A patent/AU2021250303A1/en not_active Abandoned
- 2021-03-29 EP EP21716133.0A patent/EP4126850B1/en active Active
- 2021-03-29 JP JP2022559709A patent/JP7617134B2/ja active Active
- 2021-03-29 TW TW110111402A patent/TW202204343A/zh unknown
- 2021-03-29 IL IL296823A patent/IL296823A/en unknown
- 2021-03-29 MX MX2022012067A patent/MX2022012067A/es unknown
- 2021-03-29 CN CN202180025462.7A patent/CN115697997B/zh active Active
- 2021-03-29 WO PCT/EP2021/058099 patent/WO2021198149A1/en not_active Ceased
- 2021-03-29 PE PE2022002146A patent/PE20221918A1/es unknown
- 2021-03-29 PH PH1/2022/552553A patent/PH12022552553A1/en unknown
- 2021-03-29 CA CA3176265A patent/CA3176265A1/en active Pending
- 2021-03-29 US US17/215,759 patent/US11780827B2/en active Active
-
2022
- 2022-09-23 DO DO2022000203A patent/DOP2022000203A/es unknown
- 2022-09-28 JO JOJO/P/2022/0235A patent/JOP20220235A1/ar unknown
- 2022-10-18 EC ECSENADI202280683A patent/ECSP22080683A/es unknown
- 2022-10-19 CO CONC2022/0014886A patent/CO2022014886A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3176265A1 (en) | 2021-10-07 |
| EP4126850B1 (en) | 2024-04-17 |
| CN115697997A (zh) | 2023-02-03 |
| PH12022552553A1 (en) | 2024-01-03 |
| MX2022012067A (es) | 2022-10-13 |
| DOP2022000203A (es) | 2022-11-30 |
| US20220356172A1 (en) | 2022-11-10 |
| JP7617134B2 (ja) | 2025-01-17 |
| CR20220554A (es) | 2023-01-09 |
| KR20220161454A (ko) | 2022-12-06 |
| WO2021198149A1 (en) | 2021-10-07 |
| JOP20220235A1 (ar) | 2022-09-28 |
| US11780827B2 (en) | 2023-10-10 |
| EP4126850A1 (en) | 2023-02-08 |
| AU2021250303A1 (en) | 2022-09-22 |
| BR112022018996A2 (pt) | 2022-11-01 |
| CO2022014886A2 (es) | 2022-10-31 |
| ECSP22080683A (es) | 2022-11-30 |
| AR121675A1 (es) | 2022-06-29 |
| CN115697997B (zh) | 2024-07-30 |
| TW202204343A (zh) | 2022-02-01 |
| PE20221918A1 (es) | 2022-12-29 |
| JP2023522307A (ja) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6483156B2 (ja) | 糖尿病などの疾患の治療用のピロリジンｇｐｒ４０モジュレータ | |
| US12012373B2 (en) | Cannabinoid derivatives | |
| EP4126850B1 (en) | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity | |
| JP2010524940A (ja) | ピリミジノン誘導体およびそれらの使用方法 | |
| JP2019504836A (ja) | アンドロゲン受容体アンタゴニストとしての置換チオヒダントイン誘導体 | |
| JP2012509911A (ja) | 新規の化合物 | |
| JP2012509910A (ja) | 新規の化合物 | |
| KR101567116B1 (ko) | Ｎｋ1 수용체 길항제로서의 5-[5-[2-(3,5-비스(트리플루오로메틸)페닐)-2-메틸프로파노일메틸아미노]-4-(4-플루오로-2-메틸페닐)]-2-피리디닐-2-알킬-프롤린아미드 | |
| EP4402138B1 (en) | 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives and the use thereof as medicament | |
| JP6488320B2 (ja) | 糖尿病などの疾患の治療用のピロリジンｇｐｒ４０モジュレータ | |
| EP2266976B1 (en) | Fused ring thrombin receptor antagonists | |
| US20090029979A1 (en) | 5-htx modulators | |
| JP2021042231A (ja) | 中枢神経系に関連している疾患または病態の治療に有用であるｎ−（ヘテロ）アリール置換複素環誘導体 | |
| US20190062305A1 (en) | Pyridyl or pyrazinyl compounds carrying a methyl-bound alpha-amino acid amide group | |
| WO2006115134A1 (ja) | 新規なベンゾフラン誘導体、それを含有する医薬組成物およびそれらの用途 |